Benzinga · May 14, 2026
Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10
Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $4 to $10.
RZ
NASDAQ · RZLT
Rezolute, Inc.
Healthcare · Biotechnology
$4.33
Down-$0.08 (-1.76%)
Updated Oct 6, 2026, 7:54 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 129.35M
- P/E ratio
- -1.87
- Dividend yield
- 0.00%
- 52-week range
- $2.29 – $5.64
- Volume
- 4.2M
- Avg. volume
- 1.66M
Price performance · RZLT
RZLT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
RZLT closed at $4.33 after 20 trading sessions, down 1.59% for the selected period.
- Last close
- $4.33
- Period change
- -1.59%
- Period low
- $3.84
- Period high
- $4.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.05 | $4.535 | $3.8201 | $4.33 | 4.2M |
| Oct 2, 2026 | $4.13 | $4.20 | $3.965 | $4.01 | 1.65M |
| Oct 1, 2026 | $4.14 | $4.175 | $4.04 | $4.07 | 981.72K |
| Sep 30, 2026 | $4.19 | $4.345 | $4.135 | $4.14 | 1.7M |
| Sep 29, 2026 | $4.545 | $4.57 | $4.07 | $4.09 | 1.52M |
| Sep 28, 2026 | $3.85 | $4.195 | $3.76 | $4.18 | 1.59M |
| Sep 25, 2026 | $3.99 | $4.05 | $3.8714 | $3.90 | 2.05M |
| Sep 24, 2026 | $4.03 | $4.085 | $3.835 | $3.94 | 3.87M |
| Sep 23, 2026 | $4.05 | $4.13 | $3.98 | $4.00 | 1.68M |
| Sep 22, 2026 | $3.96 | $4.09 | $3.95 | $4.04 | 928.65K |
| Sep 21, 2026 | $3.84 | $3.93 | $3.73 | $3.91 | 1.08M |
| Sep 18, 2026 | $3.95 | $3.95 | $3.665 | $3.84 | 2.53M |
| Sep 17, 2026 | $4.09 | $4.14 | $3.885 | $3.95 | 1.84M |
| Sep 16, 2026 | $4.20 | $4.23 | $3.875 | $3.98 | 2.05M |
| Sep 15, 2026 | $4.28 | $4.28 | $4.11 | $4.15 | 752.98K |
| Sep 14, 2026 | $4.18 | $4.28 | $4.09 | $4.25 | 828.03K |
| Sep 11, 2026 | $4.23 | $4.355 | $4.08 | $4.22 | 1.35M |
| Sep 10, 2026 | $4.03 | $4.35 | $3.97 | $4.17 | 2.22M |
| Sep 9, 2026 | $4.55 | $4.55 | $4.02 | $4.06 | 2.07M |
| Sep 8, 2026 | $4.51 | $4.53 | $4.37 | $4.40 | 867.08K |
Latest RZLT news
The latest Smart Investors Daily articles mentioning RZLT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RZLT research
Overview
Company profile and research snapshot.
Company profile
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Lake Street | Buy | — |
| Sep 29, 2026 | Craig-Hallum | Buy | — |
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2026 | Guggenheim | Buy | — |
| Jun 3, 2026 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · May 12, 2026
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026. Congenital Hyperinsulinism (HI) In May 2026, expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented via oral pre
Benzinga · May 12, 2026
Rezolute Q3 EPS $(0.16), Inline
Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 40.74 percent increase over losses of $(0.27) per share from the same period last year.
Yahoo · May 11, 2026
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences: Event: H.C. Wainwright 4th Annual BioConnect Investor Conference Date: May 19, 2026 Event: Jefferies Global Healthcare Conference Date: June 2-4, 2026 Management will be participating
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
